VivoSim Labs Inc - נכסים נקיים למניה בודדת VIVS

VivoSim Labs Inc is developing advanced 3D bioprinting methods for tissues by integrating AI into preclinical research. The book value per share under Russian accounting standards visualizes capital dynamics, where -0.74 is the current value of the indicator. The company's technologies help pharma behemoths optimize drug development costs, while high test accuracy minimizes harmful chemical emissions into the environment.

By holding patents for precision technologies while partially outsourcing production, VivoSim Labs Inc (VIVS) effectively accumulates intellectual and material capital. The historical book value per share reflects the ratio of net equity to the number of shares, allowing for an assessment of the real value of assets and the determination of overpayment risk relative to the fundamental base to ensure price stability.